Landscape of tumor mutational burden-high (TMB-high) and its correlation with immune checkpoint inhibitor biomarkers in gynecologic tumors

被引：0
|
作者：
Huang, Richard [1 ]
Lin, Douglas [1 ]
Danziger, Natalie [1 ]
Williams, Erik [2 ]
Elvin, Julia [1 ]
机构：
[1] Fdn Med Inc, Raleigh, NC USA
[2] UCSF & Fdn Med, San Francisco, CA USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371
引用
收藏
页码：S196 / S196
页数：1
相关论文
共 50 条
  • [21] High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
    Vareki, Saman Maleki
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [22] Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort.
    Hainsworth, John
    Friedman, Claire F.
    Kurzrock, Razelle
    Spigel, David R.
    Burris, Howard
    Sweeney, Christopher J.
    Meric-Bernstam, Funda
    Wang, Yong
    Levy, Jonathan
    Shames, David
    Schulze, Katja
    Patel, Arisha
    Swanton, Charles
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [23] Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).
    Jindal, Tanya
    Zhu, Xiaolin
    Zhang, Li
    Reyes, Kevin R.
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Shipp, Chase
    Kwon, Daniel H.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Porten, Sima P.
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [24] Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy
    Pinato, David J.
    Urus, Heather
    Newsom-Davis, Thomas
    Du Parcq, Persephone
    Belessiotis, Katherine
    Mapara, Leah
    Gupta, Nandita
    Power, Danielle
    Weir, Justin
    Wong, Ching Ngar
    Ratnakumaran, Ragu P.
    Dominy, Kathy
    Khorashad, Jamshid
    Bower, Mark
    [J]. JOURNAL OF IMMUNOTHERAPY, 2020, 43 (02) : 53 - 56
  • [25] Identification of mutational landscape predicting efficacy of immune checkpoint blockades and recurrent mutations related to high tumor mutational burden in hepatocellular carcinoma by next generation sequencing
    Li, Li
    Wen, Zhaohong
    Overman, Michael J.
    Rao, Xiaosong
    Yi, Yuting
    Guan, Yanfang
    Liang, Jun
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [26] Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression
    Li, Yunfeng
    Hu, Maitao
    Li, Lei
    Liu, Sheng
    He, Tingting
    Cheng, Chunyan
    Xu, Mian
    Yin, Xinmin
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (01)
  • [27] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [28] RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER
    Lenis, Andrew T.
    Ravichandran, Vignesh
    Hong Truong
    Reisz, Peter
    Nweji, Barbara
    Autio, Karen
    Morris, Michael
    Slovin, Susan
    Vargas, Hebert Alberto
    Laudone, Vincent
    Ehdaie, Behfar
    Reuter, Victor
    Viale, Agnes
    Schultz, Nikolaus
    Gopalan, Anuradha
    Donoghue, Mark
    Stopsack, Konrad
    Solit, David
    Abida, Wassim
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E411 - E411
  • [29] Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers
    Chen, San-chi
    Tan, Kien-Thiam
    Chen, Ming-Huang
    Hung, Yi-Ping
    Hsieh, Yi-Lin
    Jan, Yi-Hua
    Chao, Yee
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [30] Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers
    Hsieh, Yi-Lin
    Yu, Pei-Ning
    Jan, Yi-Hua
    Lai, Meng-Shao
    Wang, Woei-Fuh
    Zhuo, De-Wei
    Chen, Shu-Jen
    Cheng, Jen-Hao
    Tan, Kien Thiam
    Su, Yu-Li
    [J]. CANCER RESEARCH, 2020, 80 (16)
12345